Comparing Lifeward (NASDAQ:LFWD) and Globus Medical (NYSE:GMED)

Globus Medical (NYSE:GMED) and Lifeward (NASDAQ:LFWD) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Risk and Volatility

Globus Medical has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Lifeward has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

Valuation & Earnings

This table compares Globus Medical and Lifeward”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94 billion	3.51	$537.87 million	$3.91	19.64
Lifeward	$21.82 million	0.87	-$19.91 million	($16.82)	-0.40

Globus Medical has higher revenue and earnings than Lifeward. Lifeward is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 26.8% of Lifeward shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by insiders. Comparatively, 1.5% of Lifeward shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Globus Medical and Lifeward, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0	5	9	3	2.88
Lifeward	1	1	2	0	2.25

Globus Medical currently has a consensus target price of $99.46, indicating a potential upside of 29.54%. Lifeward has a consensus target price of $10.00, indicating a potential upside of 49.93%. Given Lifeward’s higher probable upside, analysts plainly believe Lifeward is more favorable than Globus Medical.

Profitability

This table compares Globus Medical and Lifeward’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
Lifeward	-141.28%	-235.86%	-81.72%

Summary

Globus Medical beats Lifeward on 14 of the 15 factors compared between the two stocks.

About Globus Medical

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.